Pivotal Phase 3 Study on Primary Hyperoxaluria Has High Quality Results
source: pixabay.com

Pivotal Phase 3 Study on Primary Hyperoxaluria Has High Quality Results

As seen in PR Newswire, researchers at the biopharmaceutical company OxThera AB have spent 52 weeks studying 25 patients with primary hyperoxaluria (PH), a rare disease that progressively damages the…

Continue Reading Pivotal Phase 3 Study on Primary Hyperoxaluria Has High Quality Results
An Experimental Treatment for Primary Hyperoxaluria has Earned Rare Pediatric Disease Designation
source: pixabay.com

An Experimental Treatment for Primary Hyperoxaluria has Earned Rare Pediatric Disease Designation

According to a story from BioSpace, the biopharmaceutical company Dicerna Therapeutics, Inc. has announced recently that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to…

Continue Reading An Experimental Treatment for Primary Hyperoxaluria has Earned Rare Pediatric Disease Designation